89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
89bio Inc ETNB announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in nonalcoholic steatohepatitis (NASH). The program will include two Phase 3 trials evaluating patients with NASH: • ENLIGHTEN-Cirrhosis trial will enroll patients with…#incetnb #fda #phase3 #enlightencirrhosis #f2f3 #ema #enlightenfibrosis #glp1
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Cirrhosis | Fatty Liver Disease (FLD) | Health | Liver | Liver Disease | Study | Urology & Nephrology